Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | ESRRA | P11474 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484879 | 0.82 | KMT2A (0.50) | CYP3A4PDE7AMAPTKDM4ELMNA | |
| SCHEMBL3485030 | 0.76 | MAPT (0.35) | CYP3A4NFKB1PMP22PDE7APOLB | |
| SCHEMBL3483987 | 0.75 | MGLL (0.42) | CYP3A4BACE1RECQLPOLBL3MBTL1 | |
| SCHEMBL27768764 | 0.74 | SLC6A3 (0.34) | CYP3A4NFKB1PMP22PDE7ASLC6A2 | |
| SCHEMBL3484323 | 0.73 | RHEB (0.54) | CYP3A4MAPTKDM4ERAD52SLC6A2 | |
| SCHEMBL3484255 | 0.72 | PDE7A (0.36) | CYP3A4NFKB1PMP22PDE7ABACE1 | |
| SCHEMBL3483792 | 0.71 | MAPT (0.36) | CYP3A4NFKB1PMP22PDE7APOLB | |
| SCHEMBL1964539 | 0.70 | CYP3A4 (0.56) | CYP3A4PDE7ARECQLPOLBL3MBTL1 | |
| SCHEMBL632218 | 0.69 | CYP3A4 (0.46) | CYP3A4PDE7ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3484137 | 0.68 | MRGPRX4 (0.42) | CYP3A4NFKB1PMP22PDE7ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | CYP3A4 1114/4885NFKB1 1910/4885PMP22 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.